Saiedeh Razi Soofiyani
1,2, Akbar Mohammad Hoseini
1, Ali Mohammadi
1, Vahid Khaze Shahgoli
1, Behzad Baradaran
1*, Mohammad Saeid Hejazi
3,2*1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Department of Molecular Medicine, Faculty of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A)
is an identified human oncoprotein which modulates malignant cell growth. It is
overexpressed in human prostate cancer and in most of the human malignancies.
The aim of this study was to investigate the effects of CIP2A silencing on the
sensitivity of PC-3 prostate cancer cells to docetaxel chemotherapy.
Methods: PC-3 cells were transfected using CIP2A siRNA.
CIP2A mRNA and protein expression were assessed after CIP2A gene
silencing using q-RT PCR and Western blotting. Proliferation and apoptosis were
analyzed after treatment with docetaxol using MTT assay, DAPI staining, and
flow cytometry, respectively.
Results: Silencing of CIP2A enhanced the sensitivity of PC-3
cells to docetaxel by strengthening docetaxel induced cell growth inhibition
and apoptosis against PC-3 cells.
Conclusion: Silencing of CIP2A may potentiate the cytotoxic
effects of docetaxel and this might be a promising therapeutic approach in
prostate cancer treatment.